Dr Hidehito Horinouchi is a Medical Oncologist and Assistant Chief at the National Cancer Center Hospital, Tokyo, Japan.

His research primarily focuses on multimodal treatment strategies for thoracic malignancies such as chemotherapy, targeted agents, immunotherapy, surgery, and radiotherapy.

Dr Hidehito Horinouchi has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AbbVie, AstraZeneca, BMS, Chugai/Roche, Daiichi-Sankyo, Kyowa-Kirin, MSD, Natera, Ono, and Taiho